The French VC Sofinnova has raised €333M to fund early-stage healthcare ventures, bringing the overall capital managed by the life sciences investor to €2B.
Sofinnova goals to take a position round two-thirds of the brand new fund, referred to as Sofinnova Capital IX, in European life science firms. The opposite third will likely be invested in the remainder of the world, with a give attention to North America.
Sofinnova is among the main VC companies in European life sciences. Some notable firms in its portfolio embrace GenSight Biologics, Abivax and Mission Therapeutics.
“Venture capital has wind in its sails, and VC in healthcare in Europe is now lastly coming of age,” Antoine Papiernik, Managing Companion at Sofinnova, instructed me. “The tide is elevating all boats, and as we now have been crusing on this sea for a very long time, we now have the data to seek out the best fishing spots.”
Let’s Proceed The Dialog
Be at liberty to ship us feedback about this text to [email protected] and/or touch upon that article on social media.